Abstract:Objective To investigate the effect of preemptive analgesia with parecoxib sodium on postoperative pain and inflammatory markers in patients undergoing hysteroscopic surgery.Methods Between May 2022 and May 2024, a total of 92 patients scheduled for hysteroscopic surgery were enrolled and randomly divided into a control group (n = 46, receiving conventional anesthesia) and an observation group (n = 46, receiving preemptive analgesia with parecoxib sodium) using a random number table. Comparisons were made between the two groups regarding pain and comfort measures, inflammatory markers, oxidative stress indicators, sedation and recovery parameters, as well as the incidence of adverse reactions.Results Comparisons of VAS scores, BCS scores, and levels of IL-6, TNF-α, PGE2, MDA, TAS, and ACTH at 2, 12, and 24 hours postoperatively in the observation and control groups demonstrated that they were different across the time points (P < 0.05) and between the groups (P < 0.05). Specifically, the observation group showed lower VAS scores, IL-6, TNF-α, PGE2, MDA, and ACTH levels, and higher BCS scores and TAS levels compared to the control group. No significant difference was found in the change trends of VAS and BCS scores between the two groups (P > 0.05), while significant differences were observed in the change trends of IL-6, TNF-α, PGE2, MDA, TAS, and ACTH levels (P < 0.05). The Ramsay sedation scores in the observation group were significantly higher than those in the control group (P < 0.05), and the observation group had shorter time to awakening and respiratory recovery (P < 0.05). There was no significant difference in the overall incidence of adverse reactions between the two groups (P > 0.05).Conclusion Preemptive analgesia with parecoxib sodium significantly reduces postoperative pain, attenuates the inflammatory response, and facilitates recovery in patients undergoing hysteroscopic surgery. This strategy is safe and holds promise for broader clinical application.